Diabetes Drug Receives MMA in Japan

Mitsubishi Tanabe Pharma Corp. and Daiichi Sankyo Co. Ltd., announced that Mitsubishi Tanabe Pharma has received approval to manufacture and market the SGLT2 inhibitor, Canaglu tablets (canagliflozin hydrate) 100 mg in Japan, for the treatment of patients with type 2 diabetes mellitus. Read more…

http://www.dddmag.com/news/2014/07/diabetes-drug-receives-mma-japan?et_cid=4034150&et_rid=523035093&type=headline